SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race - Pharmaceutical Technology

SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout. SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout. SK and Biohaven will now jointly progress opakalim in focal epilepsy. Credit: Teeradej / Shutterstock.com. Biohaven and SK Pharmaceuticals have struck a licensing and partnership deal which will see the pair join forces to progress an epilepsy therapy that – if approved – could become one of the first potassium channel openers to reach the epilepsy market. In…

Source: Pharmaceutical Technology